ArticleScientific reports2017

Corrigendum: CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients.

Shu Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.